# Varenicline for Cannabis Use Disorder: What Five Studies Show > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/varenicline-cannabis-use-disorder-systematic-review/ > **Published:** 2026-08-16T10:52:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:47:26-04:00 > **Clinical Summary:** Varenicline for cannabis use disorder: A systematic review of five studies involving 299 participants found mixed efficacy and tolerability results. Only o ---   CED Clinical Relevance #82 Clinical Evidence Update A peer-reviewed, preregistered [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) directly evaluated efficacy and tolerability evidence for a potential medication treatment for [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/). Clinical Insight | CED Clinic The review identified five studies with 299 total participants, including four randomized controlled trials and one case series. Results for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), tolerability, and concurrent tobacco use were inconsistent. The one high-quality study reported reduced [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and withdrawal symptoms, but the evidence base as a whole was too small and heterogeneous to support confident conclusions about efficacy or safety. Two studies were rated poor quality, two fair, and only one good. Because methods and outcomes were incompatible, the authors used narrative synthesis rather than a pooled meta-analysis. Varenicline therefore remains a research candidate, not an established [cannabis use disorder treatment](https://cedclinic.com/cannabis-use-disorder-treatment-pipeline-gains-momentum/). [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/)Varenicline[Systematic Review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/)Treatment EvidenceSafety Audience Adults and adolescents affected by cannabis use disorder, families, addiction clinicians, primary-care clinicians, and readers following cannabis treatment research Primary Topic varenicline for cannabis use disorder Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42603629/)| [**Review on CEDClinic.com  **](https://cedclinic.com/medical-marijuana-vs-cannabis-use-disorder-samhsa-2026/)**    |   [Another Review on this at CED Clinic](https://cedclinic.com/cannabis-use-disorder-biomarkers/)** A new systematic review found mixed and insufficient evidence for varenicline as a treatment for cannabis use disorder. Five studies involving 299 participants were too heterogeneous for meta-analysis, and only one was rated high quality. What This Study Teaches Us Varenicline remains an investigational option for cannabis use disorder. Across five studies, methods and outcomes differed enough that the authors used narrative synthesis rather than meta-analysis. Two studies were rated poor quality, two fair, and one good. Why This Matters Cannabis use disorder has no approved medication treatment. A plausible medication signal therefore deserves attention, but small studies, inconsistent findings, and variable quality make premature prescribing claims especially risky. Study Snapshot Study Type Preregistered systematic review with narrative synthesis Population Adolescents and adults with cannabis use or cannabis use disorder Evidence Base Five studies, 299 total participants Included Designs Four randomized controlled trials and one case series Search Coverage Nine bibliographic and trial-registry sources, with final extraction in March 2025 Primary Question Whether varenicline reduces cannabis use or cannabis use disorder outcomes Secondary Questions Tolerability and effects on concurrent tobacco use Main Result Mixed findings across studies; the single high-quality study reported reductions in cannabis use and withdrawal symptoms Tolerability Inconsistent across three studies; nausea was more frequent with varenicline in the high-quality study, without a difference in experiencing at least one adverse event Tobacco Outcome Inconsistent across four studies; the high-quality study found no difference in cigarettes per day Journal Journal of Substance Use and [Addiction Treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) Published August 15, 2026 PMID / DOI 42603629 / 10.1016/j.josat.2026.210090 Major Limitation Only five heterogeneous studies, with two rated poor quality and only one rated good Clinical Bottom Line The review does not establish varenicline as an effective or well-characterized treatment for cannabis use disorder. It identifies a signal worth testing in larger, better-designed trials while supporting continued use of established psychosocial care rather than off-label certainty. A Small Evidence Base The review found five eligible studies involving 299 participants: four randomized trials and one case series. That is a narrow foundation for judging a treatment intended for a common and clinically heterogeneous disorder. The Findings Were Mixed The single high-quality study reported reductions in cannabis use and withdrawal symptoms. Across all studies, however, efficacy findings were inconsistent, and the methods were too different for a meaningful meta-analysis. Tolerability Remains Uncertain Three studies reported tolerability outcomes, with inconsistent results. In the high-quality study, the proportion experiencing at least one adverse event did not differ between groups, although nausea was more frequent with varenicline. Tobacco Outcomes Did Not Clarify the Picture Four studies measured concurrent tobacco use and produced inconsistent findings. The high-quality study found no difference in cigarettes smoked per day during treatment. No Treatment-Efficacy Conclusion Yet Two included studies were rated poor quality, two fair, and only one good. The review authors concluded that current data are insufficient for confident conclusions about efficacy and tolerability in either youth or adults. How Strong Is This Evidence? The review was preregistered, searched multiple medical, psychological, multidisciplinary, and trial-registry sources, included peer-reviewed human studies, and formally assessed study quality and risk of bias. Where This Paper Deserves Skepticism Only five studies qualified, one was a case series, two were rated poor quality, and study methods were incompatible with meta-analysis. The most favorable result came from the single high-quality study, so replication and a larger pooled evidence base are essential. What This Paper Does Not Show This review does not prove that varenicline reduces cannabis use across patients, establishes abstinence, prevents relapse, works equally in men and women, benefits adolescents, improves concurrent tobacco outcomes, or has a fully characterized safety profile in cannabis use disorder. It does not support changing treatment without clinical supervision. How This Fits With the Broader Clinical Conversation Medication development for cannabis use disorder has repeatedly produced small or inconsistent signals. Behavioral treatments remain the better-established foundation while pharmacotherapy research continues. A recent randomized varenicline trial found no overall treatment effect on weekly cannabis-use sessions, although a sex interaction favored men. That subgroup result is important to study, but it does not reverse the review’s overall conclusion of insufficient evidence. Dr. Caplan’s Take *The most useful result here is the authors’ restraint. One better-quality study can create a promising signal, but it cannot compensate for a five-study literature with inconsistent methods and mixed findings.* *For patients, this is not a reason to seek varenicline as a proven cannabis treatment. It is a reason to support better trials and to keep current care focused on careful assessment, psychosocial treatment, withdrawal support, and concurrent tobacco or mental-health needs.* What a Careful Reader Should Take Away Varenicline is a plausible research candidate for cannabis use disorder, but this systematic review found too little consistent, high-quality evidence to call it an effective or reliably tolerated treatment. Evidence Interpretation Guide ## How to Read a Promising but Inconclusive Treatment Review A positive finding in one good study can justify more research. It cannot establish treatment efficacy when the overall literature is small, heterogeneous, and mixed. ### Four distinctions that matter **Signal versus conclusion**A favorable result in the best study is a signal, while the total evidence base determines whether a confident conclusion is possible. **Randomized trials versus a coherent evidence base**Four randomized trials sound substantial, but incompatible methods and outcomes prevented quantitative pooling. **Any adverse event versus specific adverse events**No group difference in having at least one adverse event does not mean the profiles were identical; nausea was more frequent with varenicline in the high-quality study. **Off-label possibility versus established care**Biological plausibility and early data do not make varenicline an approved or proven [cannabis use disorder treatment](https://cedclinic.com/cannabis-use-disorder-treatment-pipeline-gains-momentum/). The Research Question Does current peer-reviewed evidence show that varenicline is effective and tolerable for cannabis use disorder? The Patient Question Does this mean varenicline is a proven medication I should use to stop cannabis? The Bottom Line No. The review found an encouraging signal in one study but insufficient overall evidence for confident treatment conclusions. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight perspectives separate a research signal from treatment proof and keep efficacy, tolerability, population differences, and current care in view. #### Promising Does Not Mean Proven The review found mixed evidence and could not establish that varenicline reliably reduces cannabis use. Do not start, stop, or repurpose varenicline without a clinician who can address cannabis, tobacco, withdrawal, and mental health together. Lens takeaway Treat this as emerging research, not a self-treatment guide. #### Keep Established Care Central The literature is too small and inconsistent to support routine varenicline treatment for cannabis use disorder. Assessment, motivational and behavioral care, contingency approaches where available, withdrawal management, and co-occurring conditions remain central. Lens takeaway Do not let a single favorable study outweigh the review’s conclusion. #### Five Studies Cannot Carry Broad Claims Two studies were poor quality and only one was good. Narrative synthesis was necessary because outcomes and methods were not compatible enough for pooling. Lens takeaway The evidence base is preliminary by structure, not merely by wording. #### Outcome Inconsistency Limits Confidence Cannabis use, withdrawal, tolerability, and tobacco outcomes were not measured consistently across studies. That heterogeneity makes it difficult to estimate who might benefit, by how much, and at what cost in adverse effects. Lens takeaway Future trials need shared outcomes and adequate power. #### The New Trial Still Had a Null Overall Result A recent 174-person randomized trial reported no overall treatment effect on weekly cannabis-use sessions. A sex interaction favored men, but subgroup findings require replication and should not be generalized. Lens takeaway Newer evidence adds nuance, not certainty. #### Cannabis and Tobacco Need Separate Measurement Varenicline is established for smoking cessation, which can complicate interpretation when patients use both cannabis and tobacco. Trials should measure both substances clearly and distinguish direct cannabis effects from tobacco-related change. Lens takeaway Concurrent substance use is a design issue and a clinical issue. #### Larger Harmonized Trials Are Needed Future studies should prespecify cannabis-use, abstinence, withdrawal, retention, and adverse-event outcomes. Adequate representation and powered analyses by sex and age are necessary before subgroup claims become actionable. Lens takeaway Replication and harmonization come before practice change. #### No Approved Medication for CUD The absence of an approved medication creates pressure to overread early pharmacotherapy signals. Public communication should state clearly that evidence remains insufficient and that off-label use is not established efficacy. Lens takeaway Precision protects patients when treatment gaps are real. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Varenicline+for+Cannabis+Use+Disorder%3A+What+Five+Studies+Show&url=https%3A%2F%2Fcedclinic.com%2Fvarenicline-cannabis-use-disorder-systematic-review%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fvarenicline-cannabis-use-disorder-systematic-review%2F) [BlueSky](https://bsky.app/intent/compose?text=Varenicline+for+Cannabis+Use+Disorder%3A+What+Five+Studies+Show%20https%3A%2F%2Fcedclinic.com%2Fvarenicline-cannabis-use-disorder-systematic-review%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Varenicline for the management of cannabis use disorder: A systematic review.](https://pubmed.ncbi.nlm.nih.gov/42603629/) Related Reading at CED Clinic Continue exploring the evidence [Cannabis Craving and Cross-Substance Use](https://cedclinic.com/cannabis-craving-cross-substance-use-analysis/) Pooled trial data on cannabis craving and next-week alcohol and cigarette use during treatment. [Read the pooled trial analysis](https://cedclinic.com/cannabis-craving-cross-substance-use-analysis/) [Does Medical Cannabis Mean Lower-Risk Use?](https://cedclinic.com/medical-cannabis-label-risk/) A clinical discussion of cannabis use disorder risk, symptom burden, and why a medical label does not remove risk. [Review the clinical risk discussion](https://cedclinic.com/medical-cannabis-label-risk/) [Digital Cannabis Harm Reduction in First-Episode Psychosis](https://cedclinic.com/digital-cannabis-harm-reduction-first-episode-psychosis/) Evidence on engagement with a digital harm-reduction intervention and the limits of observed cannabis outcomes. [Read the intervention analysis](https://cedclinic.com/digital-cannabis-harm-reduction-first-episode-psychosis/) Similar Studies on CEDClinic.com Earlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Related digest item [GLP-1 agonists in addiction therapy – review](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) GLP-1 receptor agonists show promise in reducing alcohol consumption and cravings, as well as supporting nicotine abstinence. However, more research is needed for stimulant use disorders. Covers a closely related topic; this CED post is older by about 73 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) ## Frequently Asked Questions What did the systematic review examine? It examined peer-reviewed studies of varenicline for cannabis use or cannabis use disorder in adolescents and adults, including efficacy, tolerability, and concurrent tobacco use. How many studies were included? Five studies with 299 total participants were included: four randomized controlled trials and one case series. Did varenicline reduce cannabis use? Results were mixed. The single high-quality study reported reductions in cannabis use and withdrawal symptoms, but the overall evidence was insufficient for a confident conclusion. Why was there no meta-analysis? The studies used methods and outcomes that were too heterogeneous for compatible quantitative pooling, so the authors used narrative synthesis. How strong were the included studies? Two were rated poor quality, two fair quality, and one good quality. What did the review find about adverse events? Tolerability findings were inconsistent. In the high-quality study, the overall proportion with at least one adverse event did not differ, but nausea was more frequent with varenicline. Did varenicline reduce cigarette smoking? Findings across four studies were inconsistent, and the high-quality study found no difference in cigarettes per day during treatment. Is varenicline approved for cannabis use disorder? No. Varenicline is not an approved treatment for cannabis use disorder, and this review did not establish efficacy for that use. Does the review apply equally to youth and adults? No confident age-specific conclusion is possible because the total evidence base was small and heterogeneous. What is the practical takeaway? Varenicline remains a research candidate, while current treatment should continue to emphasize established psychosocial care and individualized clinical support.   ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).